Zeev Itsekson-Hayosh

Zeev Itsekson-Hayosh

Auto-generated profile, based on publicly available information

Zeev Itsekson-Hayosh

Division of Neuroradiology, Joint Department of Medical Imaging, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2016 in Journal of Neurotrauma
Verified
Journal Article
Closed access
ZIZeev Itsekson-Hayosh
Zeev Itsekson-Hayosh
ESEfrat Shavit-Stein
Efrat Shavit-Stein
AKAviva Katzav
Aviva Katzav
VRVardit Rubovitch
Vardit Rubovitch
NMNicola Maggio
Nicola Maggio
CPChaim G. Pick
Chaim G. Pick
Minimal traumatic brain injury (mTBI) is partially defined by the existence of retrograde amnesia and is associated with microscopic bleeds containing activated coagulation factors. In a previous study, we have found that mTBI immediately releases thrombin like activity in the brain, which induces amnesia by activating Protease Activated Receptor 1 (PAR-1) and blocking Long Term Potentiation (LTP). In the present study we assessed the effects of mTBI on thrombin and PAR-1 levels in the brain using the same model. Following the immediate elevation, thrombin activity returned to baseline 1 hour following the trauma and increased again 72 hours later (42% relative to control, p<0.005). These changes were associated with a significant increase in PAR-1 levels 24 hours (17%, p<0.05) and 72 hours (20%, p<0.05) following the trauma. Interestingly, the late elevation in thrombin-like activity was also associated with elevation of the major CNS thrombin inhibitor protease nexin-1, (PN-1) 72 hours following mTBI (10%, p<0.005). When thrombin was injected into the brain ventricles, an increased sensitivity to seizure like activity was detected at 72 hours post mTBI. The results are compatible with astrocyte activation following mTBI resulting in increased thrombin secretion, PAR-1 expression and seizure sensitivity.

19 February 2015 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
ZIZe’ev Itsekson-Hayosh
Ze’ev Itsekson-Hayosh
ESEfrat Shavit-Stein
Efrat Shavit-Stein
DLDavid Last
David Last
DGDavid Goez
David Goez
DDDianne Daniels
Dianne Daniels
SHSagi Harnof
Sagi Harnof

7 November 2024 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
ZIZeev Itsekson-Hayosh
Zeev Itsekson-Hayosh
FCFederico Carpani
Federico Carpani
PMPascal J. Mosimann
Pascal J. Mosimann
RARonit Agid
Ronit Agid
EHEef J. Hendriks
Eef J. Hendriks
PNPatrick Nicholson
Patrick Nicholson
BACKGROUND AND PURPOSE: Dural arteriovenous fistulas (DAVFs) exhibit varied clinical manifestations, and high-grade cases are associated with both a risk of hemorrhage and (in certain cases) dementia. Less known, however, is the association between DAVF and more subtle cognitive changes, which might not be clinically apparent without formal neurocognitive testing. This study prospectively assesses baseline cognitive changes in patients with unruptured DAVFs and looks at the effects of treatment on any such changes. MATERIALS AND METHODS: A longitudinal prospective study was conducted to formally evaluate the neurocognitive status of patients with unruptured DAVFs undergoing embolization. Pre- and posttreatment assessments included neurologic examinations and cognitive tests (Repeatable Battery for the Assessment of Neuropsychological Status and Trail-Making Test [TMT]). RESULTS: A total of 23 patients were treated, with 78% demonstrating cortical venous reflux at baseline. At baseline, 50% of patients demonstrated cognitive impairment in at least 1 cognitive domain, and this was significantly associated with cortical venous reflux (P < .05). Following treatment, significant improvements were observed in several cognitive domains. The mean change in Immediate Memory was an increase of 10.5 points (95% CI, 6.2–14.8, P < .001). Visuospatial/Constructional abilities showed a mean increase of 3.8 points (95% CI, 1.1–6.5, P = .008), while Language improved by a mean of 4.2 points (95% CI, 0.9–7.5, P = .015). Attention scores increased by a mean of 6.1 points (95% CI, 2.7–9.5, P < .001). Delayed Memory demonstrated a mean improvement of 7.4 points (95% CI, 3.5–11.3, P < .001), and the Total Repeatable Battery for the Assessment of Neuropsychological Status Score increased by a mean of 8.6 points (95% CI, 5.0–12.2, P < .001). For the TMT, the mean change in TMT-A was a decrease of 9.2 seconds (95% CI, 5.6–12.8, P < .001), indicating faster completion times. TMT-B scores decreased by a mean of 12.7 seconds (95% CI, 8.4–17.0, P < .001). The TMT B-A difference decreased by a mean of 3.5 seconds (95% CI, 0.5–6.5, P = .023), and the TMT B/A ratio showed a mean decrease of 0.18 (95% CI, 0.10–0.26, P = .002). Overall, among the patients with baseline cognitive impairment, 70% showed significant cognitive improvement following endovascular treatment, particularly in memory domains. CONCLUSIONS: In our study, 50% of patients with DAVFs had cognitive impairment when assessed with formal neurocognitive testing, with a significant link to cortical venous reflux. This cognitive impairment improved in 70% of those patients following treatment. These findings expand our understanding of how DAVF affects the brain, highlighting cognitive impairment as a critical factor. Consequently, the treatment of DAVFs should perhaps not only focus on hemorrhagic risk but also consider cognitive outcomes as a potential indicator for intervention.

26 April 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
DODavid Orion
David Orion
PLPhillip von Landenberg
Phillip von Landenberg
ZIZeev Itsekson‐Hayosh
Zeev Itsekson‐Hayosh
YSYvonne Schwammenthal
Yvonne Schwammenthal
RTRakefet Tsabari
Rakefet Tsabari
DTDavid Tanne
David Tanne

14 April 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
DODavid Orion
David Orion
ZIZe'EV Itsekson-Hayosh
Ze'EV Itsekson-Hayosh
SPShlomi Peretz
Shlomi Peretz
RMRom Mendel
Rom Mendel
GYGal Yaniv
Gal Yaniv
DGDrorit Grizim-Merkel
Drorit Grizim-Merkel
Background: Cerebral sinus venous thrombosis (CSVT) is a rare neurovascular entity, usually associated with acquired or genetic hypercoagulable states. In up to 30% of the cases it remains idiopathic. Bone marrow proliferation disorders that are associated with Janus Kinase 2 V617F mutation (JAK-2) are known causes of the systemic and cerebral thrombosis—at times despite normal blood counts—for which hematologic treatment exists. However, JAK-2 prevalence in the CSVT cases is not clear. Methods: In this retrospective analysis, data of 236 patients with CSVT admitted to two tertiary centers between 2010 and 2020 were analyzed, with emphasis on laboratory and imaging data and clinical and interventional outcomes. Results: A total of 236 patients were included in the analysis. The patients' median age was 42 years and the average age was 44 years (±19 years), with 59% female patients. JAK-2 positivity rate was 18% (among 77 patients tested for the mutation). Patients with normal blood counts on presentation comprised 36% of the JAK-2 positive cases. Other hypercoagulability states were also investigated, with the antiphospholipid syndrome (APLA) showing the highest prevalence (11%) followed by other etiologies including oral contraceptive use, Factor V Leiden, prothrombin mutation, and malignancy. Selected JAK-2, APLA, and prothrombin mutation cases showed a more severe clinical course. Conclusion: JAK-2 mutation is underdiagnosed and its screening may be warranted in the cases of idiopathic CSVT, even despite normal blood counts, to allow disease-modifying treatment and blood cell count monitoring. JAK-2, APLA, and prothrombin mutation may be associated with a more complicated clinical course.

14 October 2020 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
ZHZe'Ev Itsekson Hayosh
Ze'Ev Itsekson Hayosh
EBEiman Abu Bandora
Eiman Abu Bandora
NSNatalia Shelestovich
Natalia Shelestovich
MNMaya Nulman
Maya Nulman
MBMati Bakon
Mati Bakon
DODavid Orion
David Orion
Background Endovascularly retrieved clots are a potential resource for diagnosing stroke etiology, which may influence secondary prevention treatment. In this study we measured thrombin activity eluted by serially washing clots. Methods Clots were retrieved from 68 patients with acute ischemic stroke, freshly frozen and classified by standard criteria into proven atrial fibrillation (AF, 18 patients), atherosclerotic origin (AS, 15 patients), cryptogenic stroke (Cr, 17 patients) and other known causes (18 patients). Thawed clot samples were washed by transferring them into 1 mL buffer in seven hourly cycles and a fluorescent substrate assay was used to measure secreted thrombin activity. The clots were also examined histologically. Artificial fibrin and red blood cell-rich clots were similarly assayed for wash-eluted thrombin activity as an external control. Results Thrombin activity eluted from clots of AF origin decreased significantly with time in contrast to steady levels eluted from AS origin thrombi (P<0.0001 by repeated measures ANOVA). The Cr stroke group was indistinguishable from the AF group and differed statistically from the AS group (P=0.017 by repeated measures ANOVA). In artificial clots we found a biphasic activity pattern, with initially decreasing levels of eluted thrombin (AF pattern) and then, with continuing washes, steady eluted thrombin levels (AS pattern). Conclusions An assay measuring the change in thrombin in clots retrieved during acute stroke endovascular thrombectomy procedures may serve as a diagnostic marker of the origin of the clot. The suggested mechanism for these differences may be the clot location before its retrieval, with high blood flow causing thrombin washout in atherosclerotic clots, in contrast to atrium appendage low blood flow retaining high thrombin levels.